Last ¥1,411 JPY
Change Today -44.00 / -3.02%
Volume 136.7K
4514 On Other Exchanges
Symbol
Exchange
Tokyo
As of 2:00 AM 09/30/14 All times are local (Market data is delayed by at least 15 minutes).

aska pharmaceutical co ltd (4514) Snapshot

Open
¥1,450
Previous Close
¥1,455
Day High
¥1,454
Day Low
¥1,393
52 Week High
09/29/14 - ¥1,500
52 Week Low
10/9/13 - ¥659.00
Market Cap
43.1B
Average Volume 10 Days
103.7K
EPS TTM
¥10.19
Shares Outstanding
30.6M
EX-Date
03/27/15
P/E TM
138.5x
Dividend
¥14.00
Dividend Yield
0.99%
Current Stock Chart for ASKA PHARMACEUTICAL CO LTD (4514)

Related News

No related news articles were found.

aska pharmaceutical co ltd (4514) Related Businessweek News

No Related Businessweek News Found

aska pharmaceutical co ltd (4514) Details

ASKA Pharmaceutical Co., Ltd. is engaged in the manufacture, sale, and import/export of pharmaceuticals, veterinary medicines, quasi-drugs, foods, and medical devices. The company offers Altat for the treatment of digestive ulcers and gastritis; Prostal, a drug for the treatment of benign prostatic hypertrophy and prostate cancer; Calcitoran, a synthetic salmon calcitonin formulation; Lipidil, an antihyperlipidemic agent; and Thyradin, a drug for the treatment of hypothyroidism. In addition, it is developing BNP7787, an antineoplastic effect enhancer for antineoplastic drugs, which is in Phase III clinical trials in Europe, the United States, and Japan; and AKP-501, an infertility medication containing the genetically modified follicle-stimulating hormone. ASKA Pharmaceutical Co., Ltd. was founded in 1920 and is headquartered in Tokyo, Japan.

886 Employees
Last Reported Date: 06/27/14
Founded in 1920

aska pharmaceutical co ltd (4514) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

aska pharmaceutical co ltd (4514) Key Developments

ASKA Pharmaceutical Co.Ltd. to Report Q1, 2015 Results on Aug 04, 2014

ASKA Pharmaceutical Co.Ltd. announced that they will report Q1, 2015 results on Aug 04, 2014

Pfizer Japan, Inc., Takeda Pharmaceutical Company Limited and ASKA Pharmaceutical Co., Ltd Announces Reach Agreement to Conclude Their Contracts Regarding the Product SELTOUCH Activities

Pfizer Japan, Inc., Takeda Pharmaceutical Company Limited and ASKA Pharmaceutical Co. Ltd. announced that they have reached an agreement to conclude their contracts regarding the product SELTOUCH activities for both the poultice formulation and the tape formulation of Pfizer's transdermal absorption-type analgesic and anti-inflammatory agent SELTOUCH (SELTOUCH PAP 70, SELTOUCH PAP 140, and SELTOUCH TAPE 70) by Takeda and ASKA will be concluded. Effective from October 1, 2014, Pfizer will conduct the distribution and marketing activities for this product. The three companies will work closely to smoothly implement the marketing transfer of SELTOUCH. The companies remain committed to contributing to healthcare by providing therapeutical treatment options that address unmet needs of patients.

ASKA Pharmaceutical Co.Ltd., Annual General Meeting, Jun 27, 2014

ASKA Pharmaceutical Co.Ltd., Annual General Meeting, Jun 27, 2014.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4514:JP ¥1,411.00 JPY -44.00

4514 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 4514.
View Industry Companies
 

Industry Analysis

4514

Industry Average

Valuation 4514 Industry Range
Price/Earnings 100.0x
Price/Sales 1.0x
Price/Book 1.1x
Price/Cash Flow 138.8x
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASKA PHARMACEUTICAL CO LTD, please visit www.aska-pharma.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.